Methotrexate therapy for rheumatoid arthritis.
2015; National Institutes of Health; Volume: 91; Issue: 1 Linguagem: Inglês
Autores Tópico(s)
Autoimmune and Inflammatory Disorders Research
ResumoMethotrexate monotherapy demonstrated statistically significant and clinically relevant improvement of symptoms and physical function compared with placebo at 12 to 52 weeks. Multiple adverse effects were reported with methotrexate use, and patients were twice as likely to discontinue methotrexate therapy when compared with placebo.
Referência(s)